BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu WC, Nachbagauer R, Stadlbauer D, Solórzano A, Berlanda-Scorza F, García-Sastre A, Palese P, Krammer F, Albrecht RA. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model. Front Immunol 2019;10:756. [PMID: 31105689 DOI: 10.3389/fimmu.2019.00756] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Kong D, Chen T, Hu X, Lin S, Gao Y, Ju C, Liao M, Fan H. Supplementation of H7N9 Virus-Like Particle Vaccine With Recombinant Epitope Antigen Confers Full Protection Against Antigenically Divergent H7N9 Virus in Chickens. Front Immunol 2022;13:785975. [PMID: 35265069 DOI: 10.3389/fimmu.2022.785975] [Reference Citation Analysis]
2 Cable J, Rappuoli R, Klemm EJ, Kang G, Mutreja A, Wright GJ, Pizza M, Castro SA, Hoffmann JP, Alter G, Carfi A, Pollard AJ, Krammer F, Gupta RK, Wagner CE, Machado V, Modjarrad K, Corey L, B Gilbert P, Dougan G, Lurie N, Bjorkman PJ, Chiu C, Nemes E, Gordon SB, Steer AC, Rudel T, Blish CA, Sandberg JT, Brennan K, Klugman KP, Stuart LM, Madhi SA, Karp CL. Innovative vaccine approaches-a Keystone Symposia report. Ann N Y Acad Sci 2022. [PMID: 35029310 DOI: 10.1111/nyas.14739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Park BR, Subbiah J, Kim KH, Kwon YM, Oh J, Kim MC, Shin CH, Seong BL, Kang SM. Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes. Virology 2022;566:143-52. [PMID: 34929590 DOI: 10.1016/j.virol.2021.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Caradonna TM, Schmidt AG. Protein engineering strategies for rational immunogen design. NPJ Vaccines 2021;6:154. [PMID: 34921149 DOI: 10.1038/s41541-021-00417-1] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
5 Bull MB, Cohen CA, Leung NHL, Valkenburg SA. Universally Immune: How Infection Permissive Next Generation Influenza Vaccines May Affect Population Immunity and Viral Spread. Viruses 2021;13:1779. [PMID: 34578360 DOI: 10.3390/v13091779] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Roubidoux EK, Schultz-Cherry S. Animal Models Utilized for the Development of Influenza Virus Vaccines. Vaccines (Basel) 2021;9:787. [PMID: 34358203 DOI: 10.3390/vaccines9070787] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Roy S, Williams CM, Furuya Y. Detrimental impact of allergic airway disease on live attenuated influenza vaccine. Health Sci Rep 2021;4:e272. [PMID: 34250267 DOI: 10.1002/hsr2.272] [Reference Citation Analysis]
8 Nguyen QT, Choi YK. Targeting Antigens for Universal Influenza Vaccine Development. Viruses 2021;13:973. [PMID: 34073996 DOI: 10.3390/v13060973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Guthmiller JJ, Utset HA, Wilson PC. B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat. Viruses 2021;13:965. [PMID: 34067435 DOI: 10.3390/v13060965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
10 Jang YH, Seong BL. Immune Responses Elicited by Live Attenuated Influenza Vaccines as Correlates of Universal Protection against Influenza Viruses. Vaccines (Basel) 2021;9:353. [PMID: 33916924 DOI: 10.3390/vaccines9040353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Bullard BL, Weaver EA. Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine. Vaccines (Basel) 2021;9:257. [PMID: 33805749 DOI: 10.3390/vaccines9030257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
12 Cohen AA, Yang Z, Gnanapragasam PNP, Ou S, Dam KA, Wang H, Bjorkman PJ. Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers. PLoS One 2021;16:e0247963. [PMID: 33661993 DOI: 10.1371/journal.pone.0247963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
13 Topham DJ, DeDiego ML, Nogales A, Sangster MY, Sant A. Immunity to Influenza Infection in Humans. Cold Spring Harb Perspect Med 2021;11:a038729. [PMID: 31871226 DOI: 10.1101/cshperspect.a038729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Jiang W, Wong J, Tan HX, Kelly HG, Whitney PG, Barr I, Layton DS, Kent SJ, Wheatley AK, Juno JA. Screening and development of monoclonal antibodies for identification of ferret T follicular helper cells. Sci Rep 2021;11:1864. [PMID: 33479388 DOI: 10.1038/s41598-021-81389-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Liu WC, Nachbagauer R, Stadlbauer D, Strohmeier S, Solórzano A, Berlanda-Scorza F, Innis BL, García-Sastre A, Palese P, Krammer F, Albrecht RA. Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model. Vaccines (Basel) 2021;9:40. [PMID: 33440898 DOI: 10.3390/vaccines9010040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
16 Dhakal S, Deshpande S, McMahon M, Strohmeier S, Krammer F, Klein SL. Female-biased effects of aging on a chimeric hemagglutinin stalk-based universal influenza virus vaccine in mice. Vaccine 2020:S0264-410X(20)31510-3. [PMID: 33293159 DOI: 10.1016/j.vaccine.2020.11.057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
17 Kotomina T, Isakova-Sivak I, Kim KH, Park BR, Jung YJ, Lee Y, Mezhenskaya D, Matyushenko V, Kang SM, Rudenko L. Generation and Characterization of Universal Live-Attenuated Influenza Vaccine Candidates Containing Multiple M2e Epitopes. Vaccines (Basel) 2020;8:E648. [PMID: 33153089 DOI: 10.3390/vaccines8040648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
18 van de Ven K, de Heij F, van Dijken H, Ferreira JA, de Jonge J. Systemic and respiratory T-cells induced by seasonal H1N1 influenza protect against pandemic H2N2 in ferrets. Commun Biol 2020;3:564. [PMID: 33037319 DOI: 10.1038/s42003-020-01278-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
19 Sun W, Luo T, Liu W, Li J. Progress in the Development of Universal Influenza Vaccines. Viruses 2020;12:E1033. [PMID: 32957468 DOI: 10.3390/v12091033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
20 Shannon I, White CL, Nayak JL. Understanding Immunity in Children Vaccinated With Live Attenuated Influenza Vaccine. J Pediatric Infect Dis Soc 2020;9:S10-4. [PMID: 31848606 DOI: 10.1093/jpids/piz083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Kim KH, Jung YJ, Lee Y, Park BR, Oh J, Lee YN, Kim MC, Jeeva S, Kang SM. Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope. Virology 2020;550:51-60. [PMID: 32882637 DOI: 10.1016/j.virol.2020.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
22 Jang YH, Seong BL. Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection. Expert Opin Drug Discov 2020;15:1441-55. [PMID: 32783765 DOI: 10.1080/17460441.2020.1801629] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
23 Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell 2020;181:1036-1045.e9. [PMID: 32416070 DOI: 10.1016/j.cell.2020.04.026] [Cited by in Crossref: 1634] [Cited by in F6Publishing: 2022] [Article Influence: 817.0] [Reference Citation Analysis]
24 Demminger DE, Walz L, Dietert K, Hoffmann H, Planz O, Gruber AD, von Messling V, Wolff T. Adeno-associated virus-vectored influenza vaccine elicits neutralizing and Fcγ receptor-activating antibodies. EMBO Mol Med 2020;12:e10938. [PMID: 32163240 DOI: 10.15252/emmm.201910938] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
25 Vogel OA, Manicassamy B. Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics. Front Microbiol 2020;11:135. [PMID: 32117155 DOI: 10.3389/fmicb.2020.00135] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
26 Manenti A, Maciola AK, Trombetta CM, Kistner O, Casa E, Hyseni I, Razzano I, Torelli A, Montomoli E. Influenza Anti-Stalk Antibodies: Development of a New Method for the Evaluation of the Immune Responses to Universal Vaccine. Vaccines (Basel) 2020;8:E43. [PMID: 31991681 DOI: 10.3390/vaccines8010043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
27 Biswas A, Chakrabarti AK, Dutta S. Current challenges: from the path of “original antigenic sin” towards the development of universal flu vaccines: Flu vaccine efficacy encounters significant hurdles from pre-existing immunity of the host suggesting assessment of host immunity before vaccination. International Reviews of Immunology 2020;39:21-36. [DOI: 10.1080/08830185.2019.1685990] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
28 Strohmeier S, Amanat F, Krammer F. Cross-Reactive Antibodies Binding to the Influenza Virus Subtype H11 Hemagglutinin. Pathogens 2019;8:E199. [PMID: 31640141 DOI: 10.3390/pathogens8040199] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Jang YH, Seong BL. The Quest for a Truly Universal Influenza Vaccine. Front Cell Infect Microbiol 2019;9:344. [PMID: 31649895 DOI: 10.3389/fcimb.2019.00344] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
30 Wong J, Layton D, Wheatley AK, Kent SJ. Improving immunological insights into the ferret model of human viral infectious disease. Influenza Other Respir Viruses 2019;13:535-46. [PMID: 31583825 DOI: 10.1111/irv.12687] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
31 Francis ME, McNeil M, Dawe NJ, Foley MK, King ML, Ross TM, Kelvin AA. Historical H1N1 Influenza Virus Imprinting Increases Vaccine Protection by Influencing the Activity and Sustained Production of Antibodies Elicited at Vaccination in Ferrets. Vaccines (Basel) 2019;7:E133. [PMID: 31569351 DOI: 10.3390/vaccines7040133] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
32 Sun W, Zheng A, Miller R, Krammer F, Palese P. An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains. Vaccines (Basel) 2019;7:E117. [PMID: 31540436 DOI: 10.3390/vaccines7030117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
33 McMahon M, Asthagiri Arunkumar G, Liu WC, Stadlbauer D, Albrecht RA, Pavot V, Aramouni M, Lambe T, Gilbert SC, Krammer F. Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge. Front Immunol 2019;10:2005. [PMID: 31497029 DOI: 10.3389/fimmu.2019.02005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
34 Xie X, Zhao C, He Q, Qiu T, Yuan S, Ding L, Liu L, Jiang L, Wang J, Zhang L, Zhang C, Wang X, Zhou D, Zhang X, Xu J. Influenza Vaccine With Consensus Internal Antigens as Immunogens Provides Cross-Group Protection Against Influenza A Viruses. Front Microbiol 2019;10:1630. [PMID: 31379782 DOI: 10.3389/fmicb.2019.01630] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
35 Isakova-Sivak I, Matyushenko V, Kotomina T, Kiseleva I, Krutikova E, Donina S, Rekstin A, Larionova N, Mezhenskaya D, Sivak K, Muzhikyan A, Katelnikova A, Rudenko L. Sequential Immunization with Universal Live Attenuated Influenza Vaccine Candidates Protects Ferrets against a High-Dose Heterologous Virus Challenge. Vaccines (Basel) 2019;7:E61. [PMID: 31288422 DOI: 10.3390/vaccines7030061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
36 [DOI: 10.1101/2020.03.24.004655] [Cited by in Crossref: 83] [Cited by in F6Publishing: 15] [Reference Citation Analysis]